Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report
Frontiers in Oncology · 05.03.2026 · 16
DOI: 10.3389/fonc.2026.1779992 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 05.03.2026. Verfasst von Wenying Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second Department of Oncology, The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Hospital & Peking University Cancer Ho…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Reports of secondary mutations in mutual exclusive driver genes after resistance to targeted therapy are rare. We present a patient with Anaplastic lymphoma kinase ( ALK ) fusion lung adenocarcinoma who received sequential treatment with ALK tyrosine kinase inhibitor (TKI) (crizotinib, PFS:32.3 months and then conteltinib, PFS: 29 months). Upon further disease progression, a lung biopsy and next-generation sequencing (NGS) revealed acquired secondary driver mutations including Epidermal Growth Factor Receptor ( EGFR) L858R and ALK mutation of F1174L. Subsequently, the patient switched to third generation EGFR -TKI treatment with almonertinib. This case suggests EGFR mutation is one of the mechanisms of ALK -TKI resistance, highlights the value of re-biopsy in identifying potentially targetable resistance mechanisms and underscores the spatiotemporal heterogeneity of tumors under the selective pressure of ALK -TKI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Department of Oncology, The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Hospital & Peking University Cancer Hospital Yunnan, Kunming, China.
- The Second Department of Internal Medicine, Kunming Xishan District People's Hospital, Kunming, Yunnan, China.
Zitieren
APA
Peng, W., Duan, R., Yang, R., Qu, S., Dong, M., Chen, R., & Luo, C. (2026). Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1779992
Vancouver
Peng W, Duan R, Yang R, Qu S, Dong M, Chen R, et al. Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1779992
BibTeX
@article{Peng2026,
author = {Peng, Wenying and Duan, Ruying and Yang, Runxiang and Qu, Susu and Dong, Mengyuan and Chen, Ruofan and Luo, Chunxiang},
title = {Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1779992}
}
EUVIMED